Advanced Refractory Solid Tumors Clinical Trial
Official title:
A Prospective Multicenter Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors
This is a prospective multicenter clinical study to determine the efficacy and safety of hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for advanced multiple metastatic solid tumors
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01762410 -
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03195764 -
Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03349073 -
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05035745 -
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03863145 -
Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT04685473 -
Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT04324372 -
Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02300467 -
NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors
|
Phase 1 | |
| Suspended |
NCT01779336 -
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT04200404 -
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
|
Phase 1/Phase 2 |